AtriCure, Inc. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2026. AtriCure, Inc. is a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company operates as a single segment, developing and selling devices for cardiac tissue ablation and nerve ablation globally.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $141.2 million | $123.6 million |
| Gross Profit | $109.3 million | $92.6 million |
| Gross Margin | 77.4% | 74.9% |
| Operating Income | $0.5 million | ($5.9 million) Loss |
| Net Income | $0.1 million | ($6.7 million) Loss |
| Cash and Equivalents | $146.2 million | $99.9 million |
| Long-Term Debt | $61.0 million | $61.9 million |
| Operating Cash Flow | ($4.0 million) Used | ($11.0 million) Used |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide revenue increased 14.3% year-over-year (12.8% on a constant currency basis). Growth was driven by the United States (+14.9%) and International (+11.5%) markets.
- Profitability Turnaround: The company reported a net income of $108,000, a significant improvement from a net loss of $6.7 million in Q1 2025. Operating income turned positive at $526,000.
- Product Mix:
- Appendage Management: Revenue grew 14.9% to $48.4 million.
- Pain Management: Revenue surged 29.5% to $22.4 million.
- Open Ablation: Revenue increased 17.3% to $39.1 million.
- Minimally Invasive Ablation: Revenue declined 24.7% to $6.4 million due to reduced hybrid procedures as physicians adopt PFA catheters.
- Expense Management: Operating expenses increased 10.3% to $108.8 million, primarily due to higher personnel costs and marketing/training spend to support sales growth. However, as a percentage of revenue, operating expenses decreased from 79.7% to 77.0%.
Outlook, Risks, and Unusual Items
- Product Launches: In April 2026, the company received CE mark approval for the AtriClip FLEX-Mini and PRO-Mini devices in Europe, with a launch expected later in the year.
- Clinical Trials: The LeAAPS trial enrollment was completed in July 2025 with 6,573 patients. The BoxX-NoAF trial is ongoing with site initiation and enrollment in progress.
- Debt Facility Amendment: On January 9, 2026, the company amended its credit agreement, extending the maturity to January 9, 2029, and reducing interest rates. The facility has a $125 million capacity with $62.75 million unused as of March 31, 2026.
- Legal Contingency: The company is defending a lawsuit filed by former SentreHEART securityholders alleging breach of contract regarding PMA and reimbursement milestones. The plaintiff seeks up to $260 million plus interest. Management believes a loss is not probable or estimable and has not recorded a liability.
- Real Estate Financing: The company sold its headquarters building for $6.25 million and leased it back, recording a financing obligation. This is classified as a failed sale-and-leaseback.
Investor Verification Checklist
- Sustainability of Profitability: Verify if the Q1 2026 net income is a recurring trend or driven by one-time factors, given the company's history of accumulated deficits ($413.1 million).
- Minimally Invasive Decline: Assess the long-term impact of the 24.7% decline in minimally invasive ablation revenue due to competition from PFA catheters.
- Legal Exposure: Monitor the status of the SentreHEART litigation, as a potential loss could be material ($260 million).
- Cash Burn vs. Generation: Despite net income, operating cash flow remains negative ($4.0 million used). Verify the trajectory of working capital management and cash conversion.
- Debt Covenants: Confirm compliance with the fixed charge coverage ratio and other covenants under the amended credit facility.